Focus X

Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies

Retrieved on: 
Friday, December 2, 2022

They completed their angel round in the third quarter of 2020, which was led by Viva.

Key Points: 
  • They completed their angel round in the third quarter of 2020, which was led by Viva.
  • In addition to financial support, Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from "concept to product."
  • Viva provides efficient and high-quality screening and synthesis services for Focus-X with the help of its peptide research and development platform.
  • Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators.